

NAME	CTS AFFILIATION	DISCLOSURE	UPDATED
Sanjay Metha	PVD CTEPH Committee (Chair)	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board/ Consultant:</b> Actelion Pharmaceuticals, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Research:</b> Actelion Pharmaceuticals, Bayer, Eli Lilly, Gilead, GlaxoSmithKline, United Therapeutics, Pfizer</li> </ul>	Oct. 25 <sup>th</sup> , 2010
Mark Blostein	PVD CTEPH Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	Nov. 7 <sup>th</sup> , 2010
Kim Boutet	PVD CTEPH Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board/ Consultant:</b> Actelion Pharmaceuticals, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, GlaxoSmithKline</li> <li>▪ <b>Research:</b> Pfizer</li> </ul>	Oct. 21 <sup>st</sup> , 2010
George Chandy	PVD CTEPH Committee	<p>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</p> <ul style="list-style-type: none"> <li>▪ <b>Advisory Board/ Consultant:</b> Actelion Pharmaceuticals</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals</li> </ul>	Oct. 21 <sup>st</sup> , 2010
Carole Dennie	PVD CTEPH Committee	<p>Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</p>	Oct. 21 <sup>st</sup> , 2010

Marc de Perrot	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, Bayer</li> </ul>	Oct 23 <sup>rd</sup> , 2010
John Granton	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Program development for patient education:</b> Toronto General Hospital</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals</li> <li>▪ <b>Research:</b> Actelion Pharmaceuticals, Bayer</li> </ul>	Oct 29 <sup>th</sup> , 2010
Doug Helmerson	PVD CTEPH Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	Oct 17 <sup>th</sup> , 2010
Paul Hernandez	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Canadian Agency for Drugs and Technologies in Health, Canadian COPD Alliance, GlaxoSmithKline, Lilly, Lung Association of Nova Scotia, Merck Frosst, Novartis, Nycomed, Pfizer</li> <li>▪ <b>Speaker or CME development:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Research:</b> AstraZeneca, Actelion, Boehringer-Ingelheim, ZLB Behring, GlaxoSmithKline, Lilly, Novartis, Nycomed, Pfizer, Lung Association of Nova Scotia, Canadian Institute of Health Research, Capital Health Research Foundation</li> </ul>	Jan. 11 <sup>th</sup> , 2011

Andrew Hirsch	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, Encysive, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Speaker:</b> Pfizer</li> </ul>	March 14 <sup>th</sup> , 2011
Naushad Hirani	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, Eli Lilly, Pfizer</li> <li>▪ <b>Research:</b> Actelion Pharmaceuticals, Gilead, GlaxoSmithKline, Pfizer, United Therapeutics</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, GlaxoSmithKline</li> </ul>	Oct. 20 <sup>th</sup> , 2010
Karen Laframboise	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, Eli Lilly, GlaxoSmithKline</li> </ul>	Oct. 21 <sup>st</sup> , 2010
Robert D. Levy	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, GlaxoSmithKline, Pfizer</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals</li> </ul>	Nov. 9 <sup>th</sup> , 2010
Dale Lien	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, GlaxoSmithKline, Eli Lilly, Pfizer</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, GlaxoSmithKline</li> </ul>	Oct. 21 <sup>st</sup> , 2010

Simon Martel	PVD CTEPH Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	March 14 <sup>th</sup> , 2011
Steeve Provencher	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, Conseil du Médicament du Québec, Eli Lilly, Encysive Pharmaceuticals, GlaxoSmithKline, Ontario Public Drug Program, Unither Biotech, Pfizer,</li> <li>▪ <b>Research:</b> Actelion Pharmaceuticals, Sanofi-Aventis Canada</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion, Eli Lilly, Encysive Pharmaceuticals, GlaxoSmithKline, Nycomed, Sanofi-Aventis</li> </ul>	Oct 15 <sup>th</sup> , 2010
Fraser Rubens	PVD CTEPH Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	Oct. 22 <sup>nd</sup> , 2010
Gerard Shoemaker	PVD CTEPH Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	Oct. 21 <sup>st</sup> , 2010
John Robert Swiston	PVD CTEPH Committee	Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). <ul style="list-style-type: none"> <li>▪ <b>Advisory Board / Consultant:</b> Actelion Pharmaceuticals, Eli Lilly GlaxoSmithKline, Pfizer</li> <li>▪ <b>Research:</b> Actelion Pharmaceuticals, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, United Therapeutics</li> <li>▪ <b>Speaker / Honoraria:</b> Actelion Pharmaceuticals, Pfizer</li> </ul>	Oct. 21 <sup>st</sup> , 2010
Justin Weinkauf	PVD CTEPH Committee	Over the last two years, I have <u>not</u> had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.	Oct. 18 <sup>th</sup> , 2010